Zobrazeno 1 - 10
of 119
pro vyhledávání: '"N. Azarnia"'
Autor:
N. Azarnia, José Baselga, Alexey Manikhas, Vladimir Semiglazov, Clifford A. Hudis, R.H. Goldfarb, S. Forenza, M. Rozencweig, Javier Cortes, J. Matera, Mikhail Byakhov, L Roman, D. Lokanatha, Antonio Llombart
Publikováno v:
Annals of Oncology
Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet(®)) in combination with trastuzumabHerceptin(®) (Hoffmann-La Roche) has shown promising activity and cardi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f45146a7c7884585c5f0c0e0d6173d3c
https://pubmed.ncbi.nlm.nih.gov/24401928
https://pubmed.ncbi.nlm.nih.gov/24401928
Autor:
Shyamala C. Navada, Steven M. Fruchtman, Patrick S. Zbyszewski, Guillermo Garcia-Manero, Afoluso Ronnee Adesanya, Pierre Fenaux, N. Azarnia, Lewis R. Silverman
Publikováno v:
Blood. 134:4268-4268
Background The only approved medications for treatment of first line HR-MDS are HMAs (AZA & decitabine (DEC) in US, AZA only in EU). It is estimated that progression to Acute Myeloid Leukemia (AML) as well as median OS for these pts is Studies have d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4098496006de14e84240f4b7e621578
https://doi.org/10.1182/blood-2019-132149
https://doi.org/10.1182/blood-2019-132149
Autor:
U. Platzbecker, Thomas Prebet, N. Azarnia, Valeria Santini, Pierre Fenaux, Patrick S. Zbyszewski, David P. Steensma, Steven M. Fruchtman, Aziz Nazha, Hagop M. Kantarjian, Lewis B. Silverman, Mikkael A. Sekeres, R. Komrokji, G. Garcia-Manero, Gail J. Roboz
Publikováno v:
Leukemia Research. 55:S147-S148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd6f4875dc7ff7b077f7257ffdbc95dd
https://doi.org/10.1016/s0145-2126(17)30369-7
https://doi.org/10.1016/s0145-2126(17)30369-7
Autor:
Alexey Manikhas, S. Forenza, N. Azarnia, M. Rozencweig, J. Matera, Clifford A. Hudis, Vladimir Semiglazov, J. Baselga, L Roman, Ronald H. Goldfarb
Publikováno v:
Cancer Research. 70:P6-14
Background: Myocet™ (M) is a non-pegylated liposomal doxorubicin which exhibits reduced cardiotoxicity as compared to conventional doxorubicin. A phase 1/2 non-randomized multi-site trial combining M, trastuzumab (H) and paclitaxel (T) has resulted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::699d7300720678c5b56fec8547f08e2a
https://doi.org/10.1158/0008-5472.sabcs10-p6-14-02
https://doi.org/10.1158/0008-5472.sabcs10-p6-14-02
Publikováno v:
Annals of Oncology. 15:1527-1534
Objective: To ascertain the efficacy and tolerability of non-pegylated liposomal doxorubicin (Myocete) and epirubicin combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Methods: One hundred and sixty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ac842a696fecfa2c4969a9fdaf412d
https://doi.org/10.1093/annonc/mdh393
https://doi.org/10.1093/annonc/mdh393
Autor:
U. Platzbecker, Ehab Atallah, Lucy A. Godley, G. Garcia-Manero, Gianluca Gaidano, Maria R. Baer, Gail J. Roboz, Shyamala C. Navada, Mikkael A. Sekeres, Robert H. Collins, N. Azarnia, Aref Al-Kali, Suman Kambhampati, Lewis R. Silverman, Pierre Fenaux, Karl-Anton Kreuzer, Peter L. Greenberg, Bart L. Scott, David P. Steensma
Publikováno v:
Leukemia Research. 39:S44-S45
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfef9e7b70f4832b679f8e822710f83c
https://doi.org/10.1016/s0145-2126(15)30089-8
https://doi.org/10.1016/s0145-2126(15)30089-8
Autor:
B.R. Snyder, Suman Kambhampati, Lewis R. Silverman, Pierre Fenaux, Manoj Maniar, N. Azarnia, Gianluca Gaidano, Karl-Anton Kreuzer, Bart L. Scott, David P. Steensma, Lucy A. Godley, Michael E. Petrone, U. Platzbecker, Aref Al-Kali, Maria R. Baer, Peter L. Greenberg, Ehab Atallah, Gail J. Roboz, G. Garcia-Manero, Mikkael A. Sekeres, Robert H. Collins
Publikováno v:
Leukemia Research. 39:S57-S58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c06ba4053235b754f9028ba54ab12837
https://doi.org/10.1016/s0145-2126(15)30113-2
https://doi.org/10.1016/s0145-2126(15)30113-2
Autor:
Uwe Platzbecker, Valeria Santini, Maria R. Baer, Azra Raza, Steven M. Fruchtman, Gail J. Roboz, Suman Kambhampati, Lewis R. Silverman, Jamile M. Shammo, Aref Al-Kali, Barbara R Snyder, N. Azarnia, Pierre Fenaux, Lucy A. Godley, Guillermo Garcia-Manero, Robert H. Collins
Publikováno v:
Journal of Clinical Oncology. 34:TPS7077-TPS7077
TPS7077Background: Encouraging effects of rigosertib on overall survival (OS) seen in subgroups of pts in ONTIME informed the design of a new pivotal trial (Study 04-30; INSPIRE). This Phase III, r...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19c0b6feabab6435c390c0c9e7d2d121
https://doi.org/10.1200/jco.2016.34.15_suppl.tps7077
https://doi.org/10.1200/jco.2016.34.15_suppl.tps7077
Autor:
Robert E. Krisch, Mohammed Mohiuddin, Bahman Emani, Roger W. Byhardt, Hosny Selim, Arnold Herskovic, N. Azarnia, James D. Cox, Walter J. Curran, Kyu H. Shin, R.L. Scotte Doggett, Theodore L. Phillips, Phyllis J. Ager, Thomas J. Pajak
Publikováno v:
Cancer. 68:509-516
Since 1973, the Radiation Therapy Oncology Group (RTOG) has staged and stratified patients in non-small cell lung cancer (NSCLC) protocols according to the RTOG staging system. In 1985, the American Joint Committee on Cancer (AJCC) revised its lung c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3ac2d7557f1b565c7bef1c0bf5462d5
https://doi.org/10.1002/1097-0142(19910801)68:3<509::aid-cncr2820680311>3.0.co
https://doi.org/10.1002/1097-0142(19910801)68:3<509::aid-cncr2820680311>3.0.co
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 20:7-12
Clinical Stage III (N2) non-small cell carcinoma of the lung encompasses a large group of patients, frequently treated with radiation therapy alone, who are now considered to have borderline-resectable tumors. Pilot studies are proceeding which use c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0132b9b93d3489449fa28c59f6dc4cf1
https://doi.org/10.1016/0360-3016(91)90131-m
https://doi.org/10.1016/0360-3016(91)90131-m